Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Christine Mathieu

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of Virology|December 28, 2005
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)Hratch Arbach, Viktor Viglasky, Florence Lefeu, et al.
Anticancer Research|March 2, 2018
<i>COX2/PTGS2</i> Expression Is Predictive of Response to Neoadjuvant Celecoxib in <i>HER2</i>-negative Breast Cancer PatientsPatricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, et al.
Breast Cancer Research and Treatment|February 25, 2016
Whole exome sequencing of rare aggressive breast cancer histologiesMaria Vittoria Dieci, Veronika Smutná, Véronique Scott, et al.
Frontiers in Oncology|September 25, 2020
Adipose Tissue Properties in Tumor-Bearing BreastsIsabelle Miran, Dominique Scherer, Pauline Ostyn, et al.
Oncoimmunology|November 18, 2016
The ratio of CD8<sup>+</sup>/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i>Michaela Semeraro, Julien Adam, Gautier Stoll, et al.
BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
Cancer|June 18, 2016
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)Florence Lerebours, Sofia Rivera, Marie-Ange Mouret-Reynier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCISCorinne Balleyguier, Ariane Dunant, Luc Ceugnart, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Virology|December 28, 2005
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)Hratch Arbach, Viktor Viglasky, Florence Lefeu, et al.
Anticancer Research|March 2, 2018
<i>COX2/PTGS2</i> Expression Is Predictive of Response to Neoadjuvant Celecoxib in <i>HER2</i>-negative Breast Cancer PatientsPatricia DE Cremoux, Anne-Sophie Hamy, Jacqueline Lehmann-Che, et al.
Breast Cancer Research and Treatment|February 25, 2016
Whole exome sequencing of rare aggressive breast cancer histologiesMaria Vittoria Dieci, Veronika Smutná, Véronique Scott, et al.
Frontiers in Oncology|September 25, 2020
Adipose Tissue Properties in Tumor-Bearing BreastsIsabelle Miran, Dominique Scherer, Pauline Ostyn, et al.
Oncoimmunology|November 18, 2016
The ratio of CD8<sup>+</sup>/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i>Michaela Semeraro, Julien Adam, Gautier Stoll, et al.
BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerRoman Rouzier, Lajos Pusztai, Suzette Delaloge, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
Cancer|June 18, 2016
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)Florence Lerebours, Sofia Rivera, Marie-Ange Mouret-Reynier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCISCorinne Balleyguier, Ariane Dunant, Luc Ceugnart, et al.
Pageof 9